Pre-made Basiliximab benchmark antibody ( Whole mAb, anti-IL2RA therapeutic antibody, Anti-CD25/IDDM10/IL2R/IMD41/TCGFR/p55 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-049

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-049 Category Tag

Product Details

Pre-Made Basiliximab biosimilar, Whole mAb, Anti-IL2RA Antibody: Anti-CD25/IDDM10/IL2R/IMD41/TCGFR/p55 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Basiliximab (trade name Simulect) is a chimeric mouse-human monoclonal antibody to the ¦Á chain (CD25) of the IL-2 receptor of T cells. It is used to prevent rejection in organ transplantation, especially in kidney transplants.

Products Name (INN Index)

Pre-Made Basiliximab biosimilar, Whole mAb, Anti-IL2RA Antibody: Anti-CD25/IDDM10/IL2R/IMD41/TCGFR/p55 therapeutic antibody

INN Name

Basiliximab

Target

IL2RA

Format

Whole mAb

Derivation

Chimeric (Mouse/Human)

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Approved

Est. Status

NFD

100% SI Structure

1mim:HL/3iu3:AB:CD:HL

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

1996

Companies

Cerimon Pharmaceuticals,Novartis

Conditions Approved

Renal transplant rejection,Transplant rejection

Conditions Active

NA

Conditions Discontinued

Ulcerative colitis,Uveitis

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

IL2RA

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide